Cytokine Signalling Forum

Publications





December 18

Influence de l'Âge et de l'Insuffisance Rénale sur la Pharmacocinétique à l'État Stable du Filgotinib, un Inhibiteur Sélectif de JAK1

Namour F, Fagard L, Van der AA, Harrison P, Xin Y, Tasset C.
Br J Clin Pharmacol 2018 Dec;84(12):2779-2789. DOI:10.1111/bcp.13726

Age and renal impairment (RI) had limited impact on the pharmacokinetics (PK) of filgotinib (FIL) but, in subjects with severe RI, exposure to the FIL metabolite was increased. FIL is a selective JAK1 inhibitor that is extensively, rapidly and proportionately absorbed after oral dosing from 50–200mg. Its major metabolite has a similar JAK1 selectivity profile but with reduced potency. In humans, exposure to the metabolite is higher by approximately 16–20 fold compared with the pare...

Mots clefs: JAK, Filgotinib, Preclinical, PK-PD

Traduit par: Noack